- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04333290
Study Evaluating the Safety of Myeliviz Myelin-Targeting PET Agent
Phase 1 Study Evaluating the Safety of [11C]MeDAS Myelin-Targeting PET Agent in Humans
Study Overview
Detailed Description
Myelin PET imaging provides a new type of information regarding the integrity of the central nervous system based on molecular imaging of myelin. Preclinical studies have shown [11C] MeDAS uptake in the brain and spinal cord to be an indicator of the microstructural integrity of the tissue.
[11C]MeDAS PET (Positron Emission Tomography) scans will be performed on healthy subjects at 2 timepoints to assess for safety of the radiotracer and to assess its performance in humans. Following measurement of [11C]MeDAS pharmacokinetics and biodistribution, an optimal protocol for dosing and imaging will be established.
Study Type
Enrollment (Estimated)
Phase
- Early Phase 1
Contacts and Locations
Study Contact
- Name: Aryn Giffi Scibona, MA
- Phone Number: 216-445-8597
- Email: giffisa@ccf.org
Study Contact Backup
- Name: Rebecca Algeri, BA
- Phone Number: 216-445-3157
- Email: algerir@ccf.org
Study Locations
-
-
Ohio
-
Cleveland, Ohio, United States, 44195
- Cleveland Clinic
-
Contact:
- Aryn Giffi Scibona, MA
- Phone Number: 216-445-8597
- Email: giffisa@ccf.org
-
Principal Investigator:
- Robert Fox, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Subject reports no known physical diseases of the central nervous system including no history of mental health disorders.
- Capable of giving informed consent
- Efforts will be made to include approximately equal numbers of women and men. Efforts will be made to include individuals of diverse ethnicities, as reflected in the local clinic population.
Exclusion Criteria:
- Age <18 or >65
- History of malignant hypertension or hypertensive crisis
- Known infectious disease requiring treatment during the course of the study
- Subject reported history of substance abuse
- inability to undergo an MRI or PET scan
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Single Arm: Healthy subjects
The PET radiotracer Myeliviz ([11C]MeDAS) will be administered to healthy subjects twice and PET scans will be obtained each time.
This will allow assessment of the PET image quality, PET scan reproducibility and radiotracer distribution.
|
PET radiotracer
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Radiation dosimetry
Time Frame: Less than or equal to 2 hours
|
Whole body radiotracer uptake, as measured using PET scan image data.
Radiotracer uptake will be measured in absolute counts and using distribution volume ratios.
|
Less than or equal to 2 hours
|
Biodistribution analysis
Time Frame: Less than or equal to 2 hours
|
Organ-specific radiotracer uptake, as measured using PET scan image data.
Radiotracer uptake will be measured in absolute counts and using distribution volume ratios.
|
Less than or equal to 2 hours
|
Metabolism analysis
Time Frame: Less than or equal to 2 hours
|
Analysis of in vivo radiotracer metabolism using liquid chromatography, with quantification of relative peak areas under the curve.
|
Less than or equal to 2 hours
|
Pharmacokinetic analysis based on PET scan data
Time Frame: Less than or equal to 2 hours
|
Determination of time-dependent radiotracer distribution using PET scan image data, with time measurement in minutes, PET data measured in absolute counts, and position in the body determined by organ segmentation.
|
Less than or equal to 2 hours
|
Analysis of time-dependent radiotracer distribution based on arterial blood sampling
Time Frame: Less than or equal to 2 hours
|
Determination of time-dependent radiotracer distribution as assessed by arterial blood sampling, using scintillation counting for determination of radiotracer activity.
Time is measured in minutes and radiotracer quantity is assayed by scintillation counting with units in absolute counts.
|
Less than or equal to 2 hours
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Brain imaging characterization
Time Frame: Less than or equal to 2 hours
|
Analyze patterns of radiotracer distribution in the brain using PET scan image data.
This is an intrinsically qualitative analysis and image data will be assessed by visual inspection.
Based on findings of this first-in-human study, preliminary quantitative assessment using coregistration with structural imaging, anatomic segmentation and partial volume correction will be performed to calculate distribution volume ratios for areas of interest.
|
Less than or equal to 2 hours
|
Spinal cord imaging characterization
Time Frame: Less than or equal to 2 hours
|
Analyze patterns of radiotracer distribution in the spinal cord using PET scan image data.
This is an intrinsically qualitative analysis and image data will be assessed by visual inspection.
Based on findings of this first-in-human study, preliminary quantitative assessment using coregistration with structural imaging, anatomic segmentation and partial volume correction will be performed to calculate distribution volume ratios for areas of interest.
|
Less than or equal to 2 hours
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Robert Fox, MD, The Cleveland Clinic
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- MeDAS-001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
-
King's College LondonUniversity of ReadingCompletedHealthy | Healthy AgingUnited Kingdom
Clinical Trials on [11C]MeDAS
-
Columbia UniversityRecruitingNeurodegenerative Diseases | Amyotrophic Lateral Sclerosis | Alzheimer DiseaseUnited States
-
National Institute of Mental Health (NIMH)TerminatedDementiaUnited States
-
Hoffmann-La RocheCompletedAlzheimer's Disease, Healthy VolunteerUnited States
-
Columbia UniversityCompleted
-
Wendell Yap, MDUniversity of Kansas Medical CenterNo longer availableProstate CancerUnited States
-
Yale UniversityNational Center for Complementary and Integrative Health (NCCIH)RecruitingBehavior, HealthUnited States
-
Universitaire Ziekenhuizen KU LeuvenCHDI Foundation, Inc.Completed
-
Columbia UniversityNational Institute on Aging (NIA)RecruitingAlzheimer DiseaseUnited States
-
Mayo ClinicNational Institute of Neurological Disorders and Stroke (NINDS)Recruiting
-
Yale UniversityNational Institute of Mental Health (NIMH); National Institutes of Health (NIH)RecruitingHealthy | HIV Dementia | HIV Associated Neurocognitive Disorder | HIV EncephalitisUnited States